PeppiLibrary

Anti-aging

FOXO4-DRI peptide reference

Senolytic peptide. Disrupts FOXO4-p53 binding to selectively eliminate senescent cells.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing FOXO4-DRI notes
Default dose label5 mg
Preferred routeSubQ
Frequency labelPulsed: 3× over 1 week, then off for weeks
Storage window21 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Animal studies (mice) only; no published human clinical data

Research chemical

Route map

How records are usually labeled

1 SubQ
2 IP (research)

Rotate within abdomen.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C, use within 14–21 days.
Use-by cue21 days after mixing
Mixed vial window21 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 10 mg vial
Dose 5 mg
Route SubQ
Review 21d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for FOXO4-DRI. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

FOXO4-DRI is a synthetic peptide designed to disrupt the protein–protein interaction between FOXO4 and p53 inside senescent cells. By doing so, it triggers apoptosis selectively in senescent cells while sparing healthy ones — a 'senolytic' effect. Demonstrated rejuvenation effects in aged mice (improved fur density, kidney function, fitness). Human data extremely limited.

Also known as: FOXO4-D-Retro-Inverso.

Senolytic / longevity researchAging-phenotype reversal (animal models)

Mechanism and timing snapshot

Disrupts FOXO4-p53 interaction, freeing p53 to translocate to mitochondria and trigger apoptosis selectively in senescent cells (which depend on this interaction for survival). Healthy cells are spared.

Onset labelNot listed
Catalog onset field, when available.
Half-life label6 hr
D-retro-inverso form resists protease degradation; ~6 h plasma half-life
Duration label24 hr
Catalog duration field, when available.
IP Moderate (animal studies)
subQ Moderate (research)
oral Low

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose5 mg
Catalog dose range1 mg - 25 mg
Default routeSubQ
Frequency labelPulsed: 3× over 1 week, then off for weeks
Best time labelSame time on dosing days.
Food noteNone known.

Catalog protocol note

Pulsed dosing: 5–10 mg subQ on days 1, 3, 5; then 4-week break. Mouse-protocol-derived; no validated human protocol.

Routes and site notes

Available route labelsSubQ, IP (research)
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate within abdomen.

Chemistry

SequenceD-amino-acid retro-inverso of FOXO4 transactivation domain fragment
Amino acids23
Molecular formulaNot listed
Molecular weight2891 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size10 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note10 mg in 2 mL → 1.0 mL = 5 mg (100 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C, use within 14–21 days.
Reconstituted shelf life21 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Generally well-tolerated in animal studies
  • Transient fatigue post-dose
  • Local reactions

Contraindications and warnings

  • Pregnancy
  • Active malignancy
  • Acute infection (senescent cells participate in immunity)
  • Human safety data is virtually absent.
  • Senescent cells have homeostatic roles — wholesale clearance carries unknown risks.

Other considerations

  • Bleeding edge — most data is from one mouse study.
  • Pulsed dosing (not chronic) is the published research approach.
  • Effects of senolytic clearance in healthy humans are uncharacterised.

Evidence and regulatory context

Evidence levelAnimal studies (mice) only; no published human clinical data
FDA approvedNo
Regulatory statusResearch chemical
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteOther senolytics simultaneously
Typical cycle label1 (3 doses)
Typical break label4–12
Cycle guidancePulsed protocol with long breaks; continuous use is contrary to senolytic philosophy.

Tracking tips

  • Truly experimental — human safety unknown.
  • Pulsed protocol with long breaks is the published approach, not chronic dosing.
  • Reflect carefully on the 'senescent cells have functions' caveat before using.

References

Track it in Peppi

Keep FOXO4-DRI records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for FOXO4-DRI?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use FOXO4-DRI?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export FOXO4-DRI records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026